![Solithromycin versus ceftriaxone plus azithromycin for the treatment of uncomplicated genital gonorrhoea (SOLITAIRE-U): a randomised phase 3 non-inferiority trial - The Lancet Infectious Diseases Solithromycin versus ceftriaxone plus azithromycin for the treatment of uncomplicated genital gonorrhoea (SOLITAIRE-U): a randomised phase 3 non-inferiority trial - The Lancet Infectious Diseases](https://www.thelancet.com/cms/asset/da406e44-739d-451a-bcfd-6bfefcf012f4/gr1.gif)
Solithromycin versus ceftriaxone plus azithromycin for the treatment of uncomplicated genital gonorrhoea (SOLITAIRE-U): a randomised phase 3 non-inferiority trial - The Lancet Infectious Diseases
![Gentamicin versus ceftriaxone for the treatment of gonorrhoea (G-TOG trial): study protocol for a randomised trial | Trials | Full Text Gentamicin versus ceftriaxone for the treatment of gonorrhoea (G-TOG trial): study protocol for a randomised trial | Trials | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs13063-016-1683-8/MediaObjects/13063_2016_1683_Fig1_HTML.gif)
Gentamicin versus ceftriaxone for the treatment of gonorrhoea (G-TOG trial): study protocol for a randomised trial | Trials | Full Text
![Novel education-based intervention to reduce inappropriate antibiotic prescribing for treatment of gonorrhoea in China: protocol for a cluster randomised controlled trial | BMJ Open Novel education-based intervention to reduce inappropriate antibiotic prescribing for treatment of gonorrhoea in China: protocol for a cluster randomised controlled trial | BMJ Open](https://bmjopen.bmj.com/content/bmjopen/10/7/e037549/F3.large.jpg)
Novel education-based intervention to reduce inappropriate antibiotic prescribing for treatment of gonorrhoea in China: protocol for a cluster randomised controlled trial | BMJ Open
![Update to CDC's <I>Sexually Transmitted Diseases Treatment Guidelines, 2006</I>: Fluoroquinolones No Longer Recommended for Treatment of Gonococcal Infections Update to CDC's <I>Sexually Transmitted Diseases Treatment Guidelines, 2006</I>: Fluoroquinolones No Longer Recommended for Treatment of Gonococcal Infections](https://www.cdc.gov/mmwr/preview/mmwrhtml/figures/m614a3b.gif)
Update to CDC's <I>Sexually Transmitted Diseases Treatment Guidelines, 2006</I>: Fluoroquinolones No Longer Recommended for Treatment of Gonococcal Infections
![Gonorrhea: Treatment update for an increasingly resistant organism - Jolanta Piszczek, Renée St. Jean, Yasmin Khaliq, 2015 Gonorrhea: Treatment update for an increasingly resistant organism - Jolanta Piszczek, Renée St. Jean, Yasmin Khaliq, 2015](https://journals.sagepub.com/cms/10.1177/1715163515570111/asset/images/large/10.1177_1715163515570111-fig1.jpeg)
Gonorrhea: Treatment update for an increasingly resistant organism - Jolanta Piszczek, Renée St. Jean, Yasmin Khaliq, 2015
![A Comparison of Single-Dose Cefixime with Ceftriaxone as Treatment for Uncomplicated Gonorrhea | NEJM A Comparison of Single-Dose Cefixime with Ceftriaxone as Treatment for Uncomplicated Gonorrhea | NEJM](https://www.nejm.org/na101/home/literatum/publisher/mms/journals/content/nejm/1991/nejm_1991.325.issue-19/nejm199111073251903/production/images/img_medium/nejm199111073251903_t3.jpeg)
A Comparison of Single-Dose Cefixime with Ceftriaxone as Treatment for Uncomplicated Gonorrhea | NEJM
![Gentamicin 240 mg plus azithromycin 2 g vs. ceftriaxone 500 mg plus azithromycin 2 g for treatment of rectal and pharyngeal gonorrhoea: a randomized controlled trial - ScienceDirect Gentamicin 240 mg plus azithromycin 2 g vs. ceftriaxone 500 mg plus azithromycin 2 g for treatment of rectal and pharyngeal gonorrhoea: a randomized controlled trial - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S1198743X19304434-gr1.jpg)
Gentamicin 240 mg plus azithromycin 2 g vs. ceftriaxone 500 mg plus azithromycin 2 g for treatment of rectal and pharyngeal gonorrhoea: a randomized controlled trial - ScienceDirect
![Doxycycline vs Azithromycin: Think Twice About the 2020 CDC Guideline Update on Treatment of Gonorrhea and Chlamydia Doxycycline vs Azithromycin: Think Twice About the 2020 CDC Guideline Update on Treatment of Gonorrhea and Chlamydia](https://i2.wp.com/www.aliem.com/wp-content/uploads/2021/01/MMWR-Gonorrhea-CDC-2020-title.png?fit=951%2C353&ssl=1)
Doxycycline vs Azithromycin: Think Twice About the 2020 CDC Guideline Update on Treatment of Gonorrhea and Chlamydia
![Extra! Extra! Read all about it! 2021 Guideline Updates for Treatment of Chlamydia & Uncomplicated Gonorrhea - Southeast AIDS Education & Training Center Extra! Extra! Read all about it! 2021 Guideline Updates for Treatment of Chlamydia & Uncomplicated Gonorrhea - Southeast AIDS Education & Training Center](https://www.seaetc.com/wp-content/uploads/2021/09/Figure-1-Comparison-of-gonorrhea-and-chlamydia-recommended-treatment-regimen-recommendations-2015-vs-2021-CDC-guidelines.png)
Extra! Extra! Read all about it! 2021 Guideline Updates for Treatment of Chlamydia & Uncomplicated Gonorrhea - Southeast AIDS Education & Training Center
Multidrug-resistant gonorrhea: A research and development roadmap to discover new medicines | PLOS Medicine
![Efficacy of ertapenem, gentamicin, fosfomycin, and ceftriaxone for the treatment of anogenital gonorrhoea (NABOGO): a randomised, non-inferiority trial - The Lancet Infectious Diseases Efficacy of ertapenem, gentamicin, fosfomycin, and ceftriaxone for the treatment of anogenital gonorrhoea (NABOGO): a randomised, non-inferiority trial - The Lancet Infectious Diseases](https://www.thelancet.com/cms/attachment/92d7466c-fd80-4b43-a5fb-c87862a0aa42/gr1.gif)
Efficacy of ertapenem, gentamicin, fosfomycin, and ceftriaxone for the treatment of anogenital gonorrhoea (NABOGO): a randomised, non-inferiority trial - The Lancet Infectious Diseases
![A Comparison of Single-Dose Cefixime with Ceftriaxone as Treatment for Uncomplicated Gonorrhea | NEJM A Comparison of Single-Dose Cefixime with Ceftriaxone as Treatment for Uncomplicated Gonorrhea | NEJM](https://www.nejm.org/na101/home/literatum/publisher/mms/journals/content/nejm/1991/nejm_1991.325.issue-19/nejm199111073251903/production/images/img_medium/nejm199111073251903_t1.jpeg)